Commerce minister's intervention sought to stop enforcing barcodes on pharma exports
The Medicines and Healthcare Products Agency (MHRA) is having consultations with the pharma industry and clinical research organisations (CROs) about the European Commissions proposal to have a new clinical trials regulation.
The Medicines and Healthcare Products Agency (MHRA) is having consultations with the pharma industry and clinical research organisations (CROs) about the European Commission’s proposal to have a new clinical trials regulation. The MHRA is committed to ensure that the proposed regulatory framework does not create unnecessary burden on researchers but would only ensure making Europe Union (EU) attractive and competitive for human studies. Global and Indian pharma companies/CROs would need to provide their views by December 31, 2012.
Two companies from Karnataka namely Biocon and CRO Ecron Acunova are present in the EU. The former’s Oral Insulin IN105 underwent clinical trials in the EU and the latter has its European headquarters in Frankfurt, Germany.
The EC is keen to have one submission for both single-state and multi state trials replacing the current practice of separate submissions to the National Competent Authority and the Ethics Committees.
The proposed Regulation will replace the Clinical Trials Directive 2001/20/EC which was a concern amongst commercial and academic researchers since its introduction in 2004. The Directive reduced the attractiveness of the EU for clinical trials because it brought administrative and regulatory hassles, lacked clarity, created delays and increased costs for researchers. This led fall in the number of clinical trials conducted in the EU by 25 per cent between 2007 and 2011. Similarly in the UK too, clinical trials fell by 22 per cent over the same period. Therefore, the Government made the revision a priority in the 2011 Plan for Growth. It felt the Commission’s proposal created a more favourable environment for clinical trials in the EU, reported MHRA.
The Commission’s Impact Assessment estimates that the proposal will reduce administrative costs by 270 million Euros across the EU as a consequence of streamlining the authorisation procedure. It would also bring down the compliance costs by Euros 440 million and generate savings to the tune of Euros 34 million removing the requirements for insurance and reducing the requirements for safety reporting for low interventional trials.
“It is heartening to note the objectives of change. The EU is demonstrating that a regulator has to balance the interest of several stakeholders in the life science research ecosystem. While regulators and NGOs in some countries are primarily focused on participant safety and public health, MHRA publicly accepted that changes in regulation it effected in early 2000 slowed down the number of clinical trials in their geography by 25 per cent. In order to promote academic and pharmaceutical research towards better health care, MHRA is willing to remove hurdles and ambiguities which increases time and cost to take new medicines to clinic. This will make Europe regain its competitive edge in clinical research, said DA Prasanna, chairman and founder, Ecron Acunova.
The proposed changes to the EU’s Clinical trial regulations are timely and in the right direction. The scope of changes and the central theme: ‘Risk-adapted regulation’ would allow judicious use of regulators’ limited resources and time. It would encourage many Indian generic drugs and biosimilar product companies to conduct clinical trials in EU by reducing time, complexity and cost and allowing affordable and safe products to be made available to patients quickly. This is in line with other regulatory agencies like the US FDA, which has also proposed risk based monitoring but is lot more comprehensive. India also could look at adapting some of the important aspects of these proposed changes to simplify, streamline the regulatory process for drug development, stated Nageswara Rao, general manager, Clinigene International, a subsidiary of Biocon.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance